BHC Bausch Health Companies Inc.: תחזית צמיחת רווח נקי למניה לשנה הבאה

Bausch Health Companies (BHC) is overcoming stagnation by updating its product line for the global market. On GURU.Markets, this chart of the company's expected EPS growth for the coming year shows that the current metric is -13.70. Success is based on the cash flows of the Bausch + Lomb and Salix brands, although the debt burden and the expansion of cheap generics create serious risks for the business.

Bausch Health Companies (BHC) relies on stable revenue from its ophthalmology segment, yet high debt and patent disputes create uncertainty for the bottom line. This indicator measures the expected EPS dynamics for the coming year, allowing investors to assess market expectations regarding business growth rates by analyzing changes in earnings per share target estimates to identify hidden risks or asset undervaluation.